Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.

<h4>Background</h4>Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated.<h4>Objective</h4>To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune ch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Náthali Felícia Mineiro Dos Santos Garrett, Ana Cristina Carvalho da Costa, Elaine Barros Ferreira, Giovanni Damiani, Paula Elaine Diniz Dos Reis, Christiane Inocêncio Vasques
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ae5c174a354c41debb661420ffeed84d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ae5c174a354c41debb661420ffeed84d
record_format	dspace
spelling	oai:doaj.org-article:ae5c174a354c41debb661420ffeed84d2021-12-02T20:15:08ZPrevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.1932-620310.1371/journal.pone.0255716https://doaj.org/article/ae5c174a354c41debb661420ffeed84d2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0255716https://doaj.org/toc/1932-6203<h4>Background</h4>Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated.<h4>Objective</h4>To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and/or in combination with chemotherapy and/or radiotherapy.<h4>Materials and methods</h4>We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The protocol was registered in the International Prospective Register of Systematic Review under the number CRD42018091915. The searches were performed using the CINAHL, Cochrane CENTRAL, LILACS, LIVIVO, PubMed, Scopus, and Web of Science databases. The methodological quality of the studies was evaluated with the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data.<h4>Results</h4>A total of 9,802 articles were identified in the databases. The final sample comprised 39 studies. The evaluated drugs were ipilimumab, tremelimumab, pembrolizumab, and nivolumab. The results suggest that the most prevalent side effect was grade 1 and 2 pruritus (24%), followed by grade 1 and 2 rash (21%) and grade 1 and 2 vitiligo (10%).<h4>Conclusion</h4>The most prevalent side effects in patients treated with checkpoint inhibitors are pruritus, rash, and vitiligo, and they are rated mostly as grades 1 and 2 adverse events. Remarkably, vitiligo is most commonly found in patients treated with PD-1 inhibitors.Náthali Felícia Mineiro Dos Santos GarrettAna Cristina Carvalho da CostaElaine Barros FerreiraGiovanni DamianiPaula Elaine Diniz Dos ReisChristiane Inocêncio VasquesPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0255716 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Náthali Felícia Mineiro Dos Santos Garrett Ana Cristina Carvalho da Costa Elaine Barros Ferreira Giovanni Damiani Paula Elaine Diniz Dos Reis Christiane Inocêncio Vasques Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
description	<h4>Background</h4>Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated.<h4>Objective</h4>To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and/or in combination with chemotherapy and/or radiotherapy.<h4>Materials and methods</h4>We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The protocol was registered in the International Prospective Register of Systematic Review under the number CRD42018091915. The searches were performed using the CINAHL, Cochrane CENTRAL, LILACS, LIVIVO, PubMed, Scopus, and Web of Science databases. The methodological quality of the studies was evaluated with the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data.<h4>Results</h4>A total of 9,802 articles were identified in the databases. The final sample comprised 39 studies. The evaluated drugs were ipilimumab, tremelimumab, pembrolizumab, and nivolumab. The results suggest that the most prevalent side effect was grade 1 and 2 pruritus (24%), followed by grade 1 and 2 rash (21%) and grade 1 and 2 vitiligo (10%).<h4>Conclusion</h4>The most prevalent side effects in patients treated with checkpoint inhibitors are pruritus, rash, and vitiligo, and they are rated mostly as grades 1 and 2 adverse events. Remarkably, vitiligo is most commonly found in patients treated with PD-1 inhibitors.
format	article
author	Náthali Felícia Mineiro Dos Santos Garrett Ana Cristina Carvalho da Costa Elaine Barros Ferreira Giovanni Damiani Paula Elaine Diniz Dos Reis Christiane Inocêncio Vasques
author_facet	Náthali Felícia Mineiro Dos Santos Garrett Ana Cristina Carvalho da Costa Elaine Barros Ferreira Giovanni Damiani Paula Elaine Diniz Dos Reis Christiane Inocêncio Vasques
author_sort	Náthali Felícia Mineiro Dos Santos Garrett
title	Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
title_short	Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
title_full	Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
title_fullStr	Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
title_full_unstemmed	Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
title_sort	prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: systematic review and meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/ae5c174a354c41debb661420ffeed84d
work_keys_str_mv	AT nathalifeliciamineirodossantosgarrett prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT anacristinacarvalhodacosta prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT elainebarrosferreira prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT giovannidamiani prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT paulaelainedinizdosreis prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis AT christianeinocenciovasques prevalenceofdermatologicaltoxicitiesinpatientswithmelanomaundergoingimmunotherapysystematicreviewandmetaanalysis
_version_	1718374602516725760

Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.

Ejemplares similares